Sucampo Pharmeceuticals
Sucampo Pharmaceuticals, now a part of Mallinckrodt, is dedicated to the commercialization of innovative therapeutic solutions, including AMITIZA (lubiprostone) for pediatric functional constipation and Rescula (unoprostone isopropyl) in Japan. With a commitment to advancing development therapies, the company focuses on addressing rare diseases such as Niemann-Pick Type C and Familial Adenomatous Polyposis through its pipeline products.
Having over 150 years of experience, Sucampo emphasizes quality, integrity, and community outreach as part of its corporate culture. The merger with Mallinckrodt enhances its capabilities in delivering critical medical advancements to patients in need.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
